<DOC>
	<DOCNO>NCT02477891</DOCNO>
	<brief_summary>The objective study provide early access daratumumab treatment collect additional safety data medication commercially available available another protocol subject multiple myeloma receive least 3 prior line therapy include proteasome inhibitor ( PI ) immunomodulatory agent ( IMiD ) whose disease double refractory PI IMiD .</brief_summary>
	<brief_title>Early Access Treatment With Daratumumab ( Relapsed Refractory ) Multiple Myeloma</brief_title>
	<detailed_description>This multicenter , open-label , early access treatment protocol single-agent daratumumab subject multiple myeloma receive least 3 prior line therapy include PI IMiD whose disease double refractory PI IMiD , reside area daratumumab commercially available available another protocol , enrol another daratumumab study , eligible access enrollment another ongoing clinical study daratumumab . The study three phase : Screening phase ( 30 day prior first dose study drug ) , treatment phase ( documented progression , unacceptable toxicity , study end ) , End Treatment ( 30 day last dose study drug ) . Participants receive daratumumab ( 16 milligram per kilogram [ mg/kg ] ) intravenous infusion . Participants primarily assess overall response rate . Safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Subject must least 18 year age Subject must document multiple myeloma evidence disease progression recent prior treatment regimen define IMWG criterion : Subjects receive least 3 prior line therapy include proteasome inhibitor ( great equal [ &gt; = ] 2 cycle 2 month treatment ) IMiD ( &gt; = 2 cycle 2 month treatment ) order course treatment ( except subject discontinue either treatment due severe allergic reaction within first 2 cycles/months ) OR Subjects whose disease double refractory proteasome inhibitor ( PI ) immunomodulatory agent ( IMiD ) . For subject receive 1 type PI , disease must refractory recent one . Similarly , receive 1 type IMiD , disease must refractory recent one Subject must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 A woman childbearing potential must negative serum urine pregnancy test Screening A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control study , men must also donate sperm study 6 month receive last dose study drug Ever enrol another daratumumab study eligible enrollment another ongoing clinical study daratumumab Subject receive antimyeloma therapy receive daratumumab Enrolled another interventional clinical study therapeutic intent Subject know chronic obstructive pulmonary disease ( COPD ) Forced Expiratory Volume 1 second ( FEV1 ) less 50 % predict normal Subject know moderate severe persistent asthma within past 2 year , currently uncontrolled asthma classification Prior exposure antiCD38 monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>Early access</keyword>
</DOC>